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ABSTRACT 
Objective  
In the last decades the survival rate of preterm infants has increased substantially.
1-3
 
Despite improved intensive neonatal care the incidence of chronic lung disease in 
infants born preterm has not changed.
4-6
 The overall aim of this thesis was to 
investigate pulmonary disease in infancy, perinatal inflammatory risk factors and 
prophylaxis, with specific emphasis on the development of bronchopulmonary 
dysplasia and the effect of antenatal corticosteroids.  
 
Methods 
This thesis was built on four observational population based studies. Studies I- III were 
cohort studies. Study IV was a case-control study. Studies I and II included infants born 
from 1976 through 1997 in Sweden and investigated the effect of antenatal 
corticosteroids exposure before gestational week 34. All infants in study I were born 
before gestational week 34, whereas infants in study II were born from gestational 
week 34 or later. Study III included infants born before gestational week 37, from 1988 
through 2009 in Sweden and explored prenatal inflammatory risk factors for 
bronchopulmonary dysplasia. Study IV included infants born before gestational week 
33,  from 2005 through 2010 in Sweden, and  investigated difference in risk factors 
associated with growth restriction and inflammation between infants with 
bronchopulmonary dysplasia and infants with respiratory distress syndrome only.  
   
Results 
Infants in studies I and II had reduced risk of respiratory distress syndrome after 
exposure of antenatal corticosteroids. In term infants an increased risk of low Apgar 
score, was noticed. Study III showed that preeclampsia was the strongest prenatal risk 
factor for bronchopulmonary dysplasia. A reduced risk of bronchopulmonary dysplasia 
associated with diabetes mellitus and gestational diabetes was also found. Study IV 
showed an increased risk of bronchopulmonary dysplasia associated with long duration 
of prelabor preterm rupture of membranes, small for gestational age, low Apgar score 
and resuscitation interventions in the delivery room. 
  
Conclusions 
Studies I and II confirmed the benefits of antenatal corticosteroids in preterm infants in 
a clinical setting and also in infants born late preterm. Except for an increased risk of 
low Apgar score in term infants, no increased risks of adverse effects were found. The 
findings from Study III, with preeclampsia as the strongest risk factor and a reduced 
risk associated with diabetic disorders, suggest that an impaired angiogenesis may 
contribute to development of bronchopulmonary dysplasia. The findings from Study IV 
indicate that infants who subsequently develop bronchopulmonary dysplasia were 
likely to have been exposed to factors causing lung injury and triggering inflammation 
already during fetal life. 
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1 INTRODUCTION 
The increased survival rate of infants born preterm is generally attributed to improved 
interventions for the treatment of respiratory morbidity.
2
 Such interventions include 
antenatal corticosteroids (ACS), postnatal surfactant treatment and gentle ventilation 
strategies.
2
 Whether the beneficial effects of ACS shown in randomized controlled 
trials (RCT), are equally apparent in a clinical setting of modern neonatal care, is 
poorly studied.
7
 In addition, impaired fetal growth and adverse neurological effects 
have been reported from both human and animal studies.
8-11
 RCTs have not been able 
to sufficiently confirm or reject suspicions of short or long term adverse effects of ACS. 
 
Despite improved neonatal care, the overall incidence of bronchopulmonary dysplasia 
(BPD) has not changed over the past decade, probably due to the increased survival of 
very immature infants.
12
 BPD remains the most common complication of very preterm 
birth, causing long term morbidity and frequent re-admissions to hospital in the first 
years of life.
13
 There is no immediate cure for BPD and treatment is purely 
symptomatic. Knowledge concerning perinatal risk factors and early identification of 
infants at risk of BPD should facilitate strategies for preventing this chronic pulmonary 
disease in infancy. 
 
The overall aim of this thesis was to increase the knowledge of risk factors implicated 
in the development of BPD and to evaluate the effect of ACS used in a clinical setting 
of modern neonatal care. 
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2 BACKGROUND 
2.1 DEFINITION AND INCIDENCE OF PRETERM BIRTH 
According to the definition recognized by the World Health Organization, preterm birth 
is defined as birth before 37 gestational weeks. Birth in the interval between gestational 
weeks 34-36 is usually defined as late preterm. Very preterm birth is birth between 28-
33 gestational weeks and extremely preterm birth is defined as birth before 28 
gestational weeks.
14
  
 
Six percent of all live born infants in Sweden are born before 37 gestational weeks and 
1.2% are born before 33 gestational weeks.
1-2
 In societies with advanced medical care 
the survival rate of infants born at gestational week 28 is approximately 90-95% and at 
gestational week 24 the survival rate is approximately 50%.
15-17
  Recent research 
suggests that there are two main causes of severe prematurity; infection/inflammation 
and abnormal vascular/placental development.
18
  
 
2.2 CARDIOPULMONARY MORBIDITY AND RELATED TREATMENT 
The preterm infant has multiple organ immaturity, responsible for morbidity and 
mortality associated with preterm birth.
19-20
 In the extremely preterm infant, this organ 
immaturity includes kidneys with very low blood flow, low glomerular filtration rate, 
low tubular sodium reabsorption, and an inability to concentrate urine. The intestines 
have not developed the normal complement of digestive enzymes and peristalsis is not 
functioning normally. The skin is minimally cornified, resulting in excessive fluid and 
heat loss and poor barrier function. The brain has not developed good respiratory 
control and the immune system is naïve, antibody deficient and poorly responsive to 
infection.
19-20
  
 
2.2.1 Lung development 
Except hyperbilirubinemia, the most common morbidity affecting preterm infants is 
related to the respiratory organ system.
19-20
 The pulmonary tissues defining the 
potential air-blodd barrier in preterm infants are thicker than at term. Fetal lung 
development could be described in different stages corresponding to gestational 
weeks.
19-20
 
  
Pseudoglandular stage 
During gestational week 9-16 the preacinary airways are formed with sparse occurrence 
of capillary vessels. 
 
Canalicular stage 
During gestational week 16-26 the bronchioli continuously divide into more and 
smaller canals and the vascular supply increases steadily.
21
  
The fetal lung completes branching of the 16 generations of conducting airways by 
about gestational week 18 and develops respiratory bronchioles that terminate in 
around 240 000 saccules at gestational week 24-26.
22
 The tissue defining the potential 
air-blood barrier are thicker than at term and pulmonary microvascular development 
has not fully vascularized the saccular mesenchyme. The enzymes and lamellar bodies 
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required for surfactant synthesis and secretion are just appearing as some type II cells 
begin to mature. The fetal lung actively secretes fetal lung fluid and has not yet 
developed the ion pumps or lymphatics that assist with the clearance of fetal lung fluid. 
At the end of this period respiration becomes possible with gas exchange between 
airway and lung capillary vessels. The lung at 24 to 26 gestational weeks is in the late 
canalicular stage of development. 
 
Saccular stage 
The extent of lung development between 24-26 weeks gestation and 32 weeks is 
substantial. Extensive vasculogenesis occurs within the developing terminal saccules. 
Secondary crests are formed along with remodeling and loss of interstitial extracellular 
matrix.
23
 At 30 to 32 weeks the lung is in the saccular stage. Alveolarization of the 
saccular human lung is believed to begin about 32 week’s gestation.  
 
Alveolar stage 
Although alveoli are present in some infants at 32 weeks gestation, they are not 
uniformly present until 36 weeks during the alveolar stage of development. Further, 
only around 20% of the adult alveolar number is present in the human lung at term. The 
number of alveoli will increase to the age of eight years -  from 50 million at birth to 
about 250 million.
23
  
 
Before birth, the lungs are filled with fluid which contains a high chloride ion 
concentration. During the last two weeks before birth the amount of surfactant will 
increase. When respiration begins at birth, most of the lung fluid is rapidly absorbed by 
the blood and lymph capillaries, while a small amount is expelled via trachea and 
bronchi during the delivery process. When air is entering the alveoli, during the first 
breath, the surfactant coat prevents the development of an air-water (blood) interphase, 
with high surface tension. Without the surfactant layer, the alveoli would collapse 
during expiration (atelectasis). 
 
2.2.2 Transient tachypnea of the newborn  
Transient tachypnea of the newborn (TTN) results from delayed clearance of lung fluid 
and is a common cause of admission of late preterm or term infants to neonatal 
intensive care units. 
24
 The condition is particularly common after elective cesarean 
delivery.
25-26
  TTN often resolves spontaneously within a few days after birth. 
Conventional treatment involves supplemental oxygen, withholding enteral feeds and 
administration of intravenous fluids and antibiotics. Rarely, infants require CPAP and 
mechanical ventilation. Occasionally, some infants develop severe hypoxemia and may 
require high concentrations of oxygen, but TTN has not been associated with any long 
term complication.
27
 
 
2.2.3 Respiratory distress syndrome  
Respiratory distress syndrome (RDS) is a common disorder in preterm infants. The 
incidence is inversely related to gestational weeks at birth, 91% of infants born at 
gestational weeks 23-25, 74% at gestational weeks 28-29 and 52% at gestational weeks 
30-31 being affected.
28
 RDS is mainly caused by surfactant deficiency resulting in high 
alveoli surface tension and low lung compliance, leading to alveolar inflammation and 
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presence of hyaline membrane. In its natural course, symptoms appear shortly after 
birth and increase in severity over the first two days of life.  Clinically, RDS presents 
with early respiratory distress comprising cyanosis, grunting, retractions, and 
tachypnoea.
28
  
 
Surfactant replacement therapy is crucial in the management of RDS.
29
 Surfactant 
could be given as a prophylactic or as a rescue therapy, but administration requires 
intubation.
30
 Mechanical ventilation can be life-saving but could also cause lung injury 
and, wherever possible, nasal CPAP should be used.
28, 31
 In order to induce endogenous 
surfactant production, prophylactic treatment with ACS is recommended to all Swedish 
women presenting with imminent preterm delivery up to gestational week 32+6.
7, 32
 
The introduction of ACS, surfactant treatment and new ventilator strategies have 
resulted in major improvements in the clinical course and outcomes of preterm infants 
with RDS. For infants with RDS to have best outcomes, it is essential that they have 
optimal supportive care, including maintenance of normal body temperature, proper 
fluid management, good nutritional support, management of the ductus arteriosus and 
support of the circulation to maintain adequate tissue perfusion.
28, 33
 However, despite 
improved treatment strategies, RDS may progress into severe hypoxia, respiratory 
failure and death or to BPD. 
 
2.2.4 Air leak syndrome 
Air leak syndrome includes pulmonary interstitial emphysema (PIE), pneumothorax, 
pneumomediastinum, pneumopericardium, pneumoperitoneum, subcutaneous 
emphysema and systemic air embolism. Leakage of gas from the airways into the 
pulmonary interstitial space is mostly seen as a complication from ventilator therapy, 
most commonly in preterm infant with fragile and immature lungs.
34-35
 The incidence 
of air leaks in the newborn is inversely related to the birth weight of the infant, 
especially in very-low-birth-weight infants. When the air leak is asymptomatic and the 
infant is not mechanically ventilated, there is usually no specific treatment. Emergent 
needle aspiration and/or tube drainage are necessary in managing tension 
pneumothorax or pneumopericardium with cardiac tamponade. To prevent air leak 
syndrome, gentle ventilation with low pressure, low tidal volume, low inspiratory time, 
high rate, and judicious use of positive end expiratory pressure are the keys to caring 
for mechanically ventilated infants.  
 
2.2.5 Meconium aspiration syndrome 
Meconium aspiration syndrome (MAS) is a common cause of severe respiratory 
distress in term or near term infants and associated with a significant respiratory 
morbidity and mortality.
36-37
 MAS results from aspiration of meconium during 
intrauterine gasping or during the first few breaths. Fetal hypoxic stress can stimulate 
colonic activity, resulting in the passage of meconium and also stimulate fetal gasping 
and result in meconium aspiration in utero. The pathophysiology of MAS is 
multifactorial and includes acute airway obstruction, surfactant dysfunction or 
inactivation, chemical pneumonitis with release of vasoconstrictive and inflammatory 
mediators and persistent pulmonary hypertension of newborn (PPHN). This disorder 
can be life threatening, often complicated by respiratory failure, pulmonary air leaks, 
and PPHN. Approaches to prevent MAS have changed over time with collaboration 
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between obstetricians and pediatricians forming the foundations for care. The use of 
surfactant and inhaled nitric oxide (iNO) has led to decreased mortality and reduced the 
need for extracorporeal membrane oxygenation (ECMO) use. 
  
2.2.6 Persistent Pulmonary Hypertension of the newborn  
PPHN is a severe pulmonary disorder which occurs at a rate of one in every 500 live 
birth.
38
  The main cause of pulmonary hypertension in newborn infants is failure of the 
pulmonary circulation to dilate.
39-40
 This syndrome is characterized by sustained 
elevation of pulmonary vascular resistance, causing extrapulmonary right-to-left 
shunting of blood across the ductus arteriosus and foramen ovale and severe 
hypoxemia.
40
 Symptoms of severe hypoxemia usually appear directly after birth, but, 
occasionally, symptoms can develop several hours or even days after birth. There are 
many unresolved issues regarding the patho-physiology but PPHN is often secondary to 
other morbidities, such as congenital diaphragm hernia, severe RDS, septicemia, 
meconium aspiration or asphyxia.
40-41
 In addition, exposure to selective serotonin 
reuptake inhibitors during pregnancy has been shown to increase the risk of PPHN in 
the infant.
41
 Treatment with iNO, a potent selective pulmonary vasodilator has made 
management of PPHN easier than it was a decade ago. Nevertheless, the mortality rate 
remains unchanged (10-15%) and 7-20% of the survivors develop long-term sequelae, 
such as hearing deficit, chronic lung disease, and intracranial bleed.
38, 41
  
 
2.2.7 Patent Ductus Arteriosus  
In fetal circulation the ductus arteriosus connects the pulmonary artery with the aorta. 
In this way, oxygenated blood from the placenta is distributed blood to internal organs, 
by-passing the lungs. The ductus arteriosus closes rapidly after term birth due to 
increased arterial blood oxygen tension (PaO2) and decreased circulating prostaglandin 
levels. In preterm infants, the ductus arteriosus can sometimes persist and a 
hemodynamically significant left-to-right shunt will develop.  A persistent patent 
ductus arteriosus (PDA) impairs pulmonary mechanics, prolonging the need for 
mechanical ventilation and increasing the risk of pulmonary hemorrhage and altering 
alveolar surface area.
42
 Pharmacologic closure of PDA with non-steroid anti-
inflammatory drugs (indometacin or ibuprofen) inhibits prostaglandin synthesis and 
induces ductal constriction. Pharmacological treatment is indicated to prevent the 
negative effect on pulmonary function and alveolar development.
43-44
 In some infants, a 
surgical closure of PDA is required. Population-based, observational studies suggest 
that surgical ligation is an independent risk factor for the development of BPD.
45-46
  
However, it is difficult to determine whether the increased risk is due to the ligation 
itself and the effect of surgery, or to other factors, such as prolonged left-to-right PDA 
shunt, which might coexist in infants who require ligation.  
 
2.2.8 Bronchopulmonary dysplasia 
BPD is synonymous to chronic lung disease which is a serious disorder affecting 
preterm infants. See a detailed description in section 2.3 below. 
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2.3 BRONCHOPULMONARY DYSPLASIA  
2.3.1 Incidence 
The overall incidence of BPD in preterm newborns has not changed over decades and 
has been reported to be approximately 20%.
5
 In preterm newborns weighing <1500 
gram, the incidence of BPD is between 15-47%.
47
  In Sweden around 2400 infants were 
diagnosed with BPD between the years 1988 and 2009.  
 
2.3.2 Definition 
Various criteria have been used to diagnose BPD. Traditionally, infants are diagnosed 
as having BPD if they have been oxygen dependent for at least 28 days after birth.
48
 
The US National Institutes of Health (NIH) have presented diagnostic criteria that 
include evaluation of oxygen need at 36 weeks postmenstrual age (gestational age plus 
chronological age).
49-50
 If an infant has been oxygen dependent for at least 28 days but 
is breathing room air at 36 weeks postmenstrual age, the condition is considered mild 
BPD. Moderate BPD is defined as a need for <30% O2 at 36 weeks of postmenstrual 
age. Severe BPD is defined as need for >30% O2 (with or without positive pressure 
ventilation or continuous positive pressure respiratory support).
50-51
 To enable a more 
accurate diagnosis, an oxygen reduction test is used to determine whether 
supplementary oxygen is still required.
49
 
 
2.3.3 Etiology 
Knowledge concerning the etiology of BPD is limited and development is 
multifactorial.
52
 The most important predictor for BPD development is degree of 
prematurity but a myriad of other fetal and postnatal factors may contribute. 
23, 51, 53
  
The interactive role of pre- and postnatal growth restriction and inflammation (alone or 
in association with infection) has been suggested to be keystones for BPD 
pathogenesis.
54-55
 
56
 
 
High concentrations of inflammatory markers, such as IL-6 and TNF-alpha have been 
found in cerebrospinal fluid in infants with BPD.
57
 One inflammatory mediator that 
may be central to fetal inflammation and BPD is IL-1. IL-1 is an early acute phase 
response cytokine in alveolar macrophages and in lung epithelium, but it is also stored 
as a procytokine in inflammasomes, (i.e. intracellular organelles that have primarily 
been identified in inflammatory cells).
58-59
 In a fetal sheep model of chorioamnionitis, 
IL-1 mediated most of the lung and systemic inflammation induced by 
lipopolysaccharide.
60
 
 
However, the exact mechanism responsible for the severe alterations in the pulmonary 
structure and function of the neonate with BPD is still unknown and biomarkers for 
BPD are in research focus since prediction of which infant that will develop BPD is so 
difficult. Genetic factors may also contribute to BPD at multiple levels. 
 
2.3.4 Risk factors 
The most important predictor for BPD development is short gestational age but fetal 
growth restriction, preeclampsia, RDS and mechanical ventilation are other recognized 
risk factors.
12, 61-63
 Pneumonia and other serious infections might also increase risk of 
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developing BPD but the role of prenatal infection, such as chorioamnionitis, is 
unclear.
57, 61-62, 64-65
 
 
Moreover, clinical observations indicate that fetal exposure to inflammation may have 
both detrimental and beneficial effects on the preterm lung.
54
 It has been proposed that 
fetal exposure to chronic inflammation may induce lung maturation and thereby reduce 
the incidence of RDS but may, on the other hand, promote the development of BPD.
54
 
 
2.3.5 Treatment 
Infants with BPD will receive intense supportive care but there is no available medical 
treatment that can immediately cure BPD. Thus, treatment is purely symptomatic.
47, 66
 
 
Postnatal steroids have been used for many years in the treatment/prevention of BPD 
based on meta-analyses suggesting decreased rates of BPD with steroid use.
67-70
 
However, concerns over adverse effects on subsequent negative neuro-developmental 
outcome have contributed to a significant reduction in routine use of postnatal 
steroids.
71
 The current understanding is that systemic postnatal steroids should be 
reserved for ventilated infants who cannot be weaned from ventilator support.
72-74
 In 
addition, postnatal steroids given as inhalation have not been shown to reduce 
outcomes of death or BPD, nor did inhaled postnatal steroids impact on short term 
outcomes such as failure to extubate, oxygen dependency or total duration of 
mechanical ventilation.
72
 
 
Inhaled NO (iNO) is primarily used for the treatment of PPHN but may also be used as 
prevention of BPD. Treatment with iNO may improve ventilation-perfusion mismatch 
and oxygenation, lower pulmonary arterial pressure, reduce lung inflammation and 
thereby attenuate the pathophysiology of respiratory distress syndrome. However, the 
National Institute of child Health and Human development, USA (NICHD) trial of 
inhaled nitric oxide in preterm infants did not show a difference in the primary outcome 
of BPD and death between controls and those having received iNO.
75
  Therefore, iNO 
remains a controversial treatment for premature infants with severe respiratory 
failure.
76-77
  
 
Recent experience in neonatology suggests that combining less invasive care strategies 
that avoid excessive oxygen and mechanic ventilation, decreasing postnatal infection 
and optimize nutrition, may decrease the incidence and severity of BPD.
31, 78-79
 
 
2.3.6 Clinical characteristics of BPD 
The clinical characteristics and the natural history of infants affected by BPD have 
changed considerably over the last decades, probably due to advances in perinatal care 
and neonatal respiratory therapy. In the past, infants developed BPD after severe 
respiratory failure, frequently compounded by a PDA, PIE and/or infection 
necessitating high-pressure ventilation and supplementary oxygen concentration.
80
  
The former severe BPD has been replaced by a clinically milder form, without or with 
mild RDS in the first days of life, that responds rapidly to surfactant therapy but 
requires prolonged ventilator support because of poor respiratory effort.
21
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2.3.7 Long term outcome of BPD 
Patients diagnosed with BPD who survive the first month of life have a 30% increased 
risk of dying in the first year of life.
66, 81
 The main causes of death in these patients are 
respiratory failure, systemic infections and cor-pulmonale. Patients with BPD have 
frequent respiratory infections during the first two years of life and an increased 
frequency of bronchial hyperactivity.
66, 81
 
 
Affected children require frequent readmissions to hospital, and, although lung growth 
and remodeling result in progressive improvement in lung function, airflow 
abnormalities may remain. After dismissal from hospital, most infants with BPD will 
require continued medication, breathing treatments and oxygen during their first year of 
life. The lung problems can linger into childhood, adolescence and even into adult 
ages.
51, 82-83
 Neurological development is affected in approximately 40% of patients 
with BPD.
84
  
 
2.4  ANTENATAL CORTICOSTEROIDS 
In 1972, Liggins and Howie published a landmark article demonstrating that ACS 
significantly reduced the frequency of RDS and neonatal mortality. 
85-86
  Thereafter, 
ACS treatment was gradually introduced worldwide and ACS treatment is now an 
established intervention in the prevention of RDS in premature infants.  
 
In fetal lung maturation, ACS accelerates the effect of endogenous corticosteroids and 
induces the production of all the components of the surfactant system. ACS may also 
facilitate clearance of lung fluid by activating the epithelial sodium channels and 
increasing ion transport, but this mechanism has not been confirmed. The net results are 
improved lung function, better response to surfactant and improved survival.
48
 Other 
proposed beneficial effects of ACS under debate, are liver maturation and reduction of 
the risk of neonatal jaundice requiring phototherapy. In addition to reduction of RDS, 
RCTs have shown that ACS treatment also reduces the risk of neonatal death, 
intraventricular hemorrhage and necrotizing enterocolitis.
7
  
 
Current European Consensus Guidelines recommends ACS therapy in all pregnancies 
with imminent preterm delivery before 35 weeks’ gestation and concludes that there is 
strong evidence for the role of a single course of antenatal steroids in RDS prevention, 
but the potential benefit and long-term safety of repeated courses is unclear.
28
 
Betamethasone and dexamethasone have both been used to enhance fetal lung maturity. 
Previous observational cohort studies have suggested an increased rate of cystic 
periventricular leucomalacia associated with dexamethasone but this could not be 
confirmed in a Cochrane Review.
87
  At present, there is no definite recommendation on 
the choice of steroid.  
 
In Sweden, the administration of ACS was gradually introduced during a 20 year 
period with great differences in starting year of routine use between different maternity 
wards.
88
 It is estimated that by year 1997 all maternity wards in Sweden had introduced 
this routine. Currently, ACS is offered to all women presenting with imminent preterm 
delivery before gestational week 33.
28
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In contrast to the beneficial effect of ACS on RDS, the effects on BPD have been less 
obvious. Some studies report positive effects, whereas others have seen no effects or 
even negative effects.
89-92
     
 10 
3 AIMS 
The overall aim of this thesis was to investigate pulmonary disease in infancy, in 
particular perinatal inflammatory risk factors for pulmonary disease with specific 
emphasis on the development of BPD. Further, the aim was to study prophylaxis of 
pulmonary disease in the neonate, with specific emphasis on the effect of ACS. 
 
The specific aims of the included studies were 
 To assess whether ACS treatment affects neonatal mortality, RDS, 
intraventricular hemorrhage, retinopathy of prematurity, BPD, and long-term 
outcome such as epilepsy and cerebral palsy in children born before gestational 
week 34 (Study I); 
 
 To investigate whether exposure of ACS before gestational week 34 was 
associated with reduced risk of RDS and BPD in infants born late preterm or 
term, and if there were any increased risks of deviant fetal growth, other 
adverse neonatal outcomes, or epilepsy, cerebral palsy or diabetes during 
childhood (Study II); 
 
 To identify prenatal risk factors for BPD, focusing on inflammation, and to 
investigate whether maternal inflammatory diseases, pregnancy related diseases 
and related pharmacological treatment during pregnancy, may affect the risk of 
BPD development in preterm infants (study III); 
 
 To identify factors that may affect the development of BPD in infants by 
comparing perinatal growth and factors related to inflammation between infants 
with BPD and infants with RDS only, and also comparing the occurrence of 
other factors related to these two disease entities (Study IV). 
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4 METHODS 
Study designs 
All papers in this thesis are based on newborn infants, born during a period of over 
thirty years; from 1976 through 2010 in Sweden. The majority was born preterm before 
37 gestational weeks. Two different study designs were used; cohort studies (studies I-
III) and a case-control study (study IV).  
 
Data sources 
The Swedish national health registers (the Medical Birth Register, the Patient Register, 
the Cause of Death Register and the Prescribed Drug Register) were the primary 
sources of data in studies I-III, whereas the Swedish Perinatal Quality Register 
neonatal (PNQn) was the primary source of data in study IV. Diagnoses in all the 
registers are classified and recorded by the treating physician according to the 
International Classification of Diseases (ICD) at the time of discharge, according to 
current ICD version. All registers include the national registration number assigned to 
each Swedish resident, which enabled us to merge data from different registers for a 
specific infant. 
 
The Medical Birth Register 
The Swedish Medical Birth Register was established 1973 and contains information on 
more than 99% of all births in Sweden, including data on the mother, pregnancy, 
delivery and neonate, and diagnoses at discharge from the hospital.
93
 Since 1994, 
information on drug use from antenatal care has been recorded in the Swedish Medical 
Birth Register and subsequently, this information is converted into the World Health 
Organization Anatomical Therapeutic Chemical (ATC) classification. 
 
The Prescribed Drug Register 
Information on dispensed drugs during pregnancy is found in The Prescribed Drug 
Register which started in July 2005. Drugs in the register are recorded according to 
ATC. The Prescribed Drug Register contains information with unique patient 
identifiers for all prescriptions dispensed to the whole population of Sweden. For 
prescribed drugs, the register includes data on dispensed item, substance, brand name, 
formulation, package size, dispensed amount, dosage, expenditure and reimbursement. 
The register does not include information on over-the-counter medications nor on drug 
used or administered in hospitals. Information on drug treatment during a hospital stay 
is noted in the individual medical record, but this information is currently not 
forwarded to the Prescribed Drug Register.
94
  
 
The Patient Register  
The Patient Register includes dates of each hospital admission and discharge, as well as 
main discharge diagnosis and secondary diagnoses. From 2001 information on 
outpatient care is also covered.
95
  
 
The Cause of Death Register  
The Cause of Death Register contains dates and causes of all deaths among Swedish 
residents.  
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The Swedish Perinatal Quality Register neonatal  
The PNQn was created in 2000 as a local hospital register. From January 2008 and 
onwards, PNQn contains data on all infants admitted to the neonatal units in Sweden. 
Data in the register is obtained from standardized questionnaires prospectively filled by 
the physicians during neonatal care and includes information on resuscitation, 
ventilator support, specified pharmacological treatment, other interventions and 
morbidity.  
 
4.1 STUDY POPULATION IN STUDIES I AND II 
General considerations 
With the overall aim of evaluating the comprehensive health consequences of the 
widespread routine treatment with ACS to women with imminent preterm delivery, 
studies I and II were performed. Further, because adverse effects are typically much 
less common than the intended positive effects of drugs, RCTs conducted to evaluate 
prophylactic interventions, are seldom large enough to provide an adequate assessment 
of drug safety. Therefore, the primary objective when designing studies I and II was to 
evaluate short and long-term adverse effects of ACS, in the population that actually 
received the treatment in the real clinical setting.  
 
Study populations 
The cohorts in studies I and II were identified through the Swedish Medical Birth 
register during the years 1976 through 1997. The time period mirrors the years during 
which ACS treatment was established as routine prophylaxis in Sweden.  
 
Study I included live-born singleton infants, born before gestational week 34. The 
gestational age limit was based on the results from questionnaires and telephone 
interviews with physicians at Swedish maternity wards (performed prior to studies I 
and II), which showed that several Swedish hospitals administered corticosteroids up to 
gestational week 34.
88
 In total, 7 827 infants were included and followed up to 9 years 
of age or to date of death.  
 
Study II included singleton infants, stillborn or live-born to women who were 
hospitalized due to imminent preterm delivery before 34 gestational weeks, but who 
eventually delivered late preterm or term. In total, 11 873 infants were included and, of 
these, 3 550 were born late preterm (gestational weeks 34 - 36), and 8 323 were born at 
term (gestational week 37 or later). The children were followed to their 11
th
 birthday or 
date of death.  
 
4.2 EXPOSURE ALGORITHM IN STUDIES I AND II 
Studies I and II used the same exposure algorithm to categorize an infant into the 
exposed or the unexposed cohort.  
 
Exposure status at the hospital level 
In Sweden, routine administration of ACS was gradually introduced over a 20 year 
time period. There was a great variability in starting year between different maternity 
wards, which opened the opportunity to use a novel exposure algorithm. If an infant 
was born at a maternity ward which routinely offered ACS prophylaxis, the infant was 
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classified as exposed. Conversely, if an infant was born at a maternity ward that had not 
established this intervention, the infant was classified as unexposed. In study II (in 
which delivery occurred weeks or months after ACS exposure) the exposure algorithm 
was related to the time period when the mothers were hospitalized due to imminent 
preterm delivery. 
 
To identify hospital routines on ACS prophylaxis, we combined information obtained 
from written questionnaires to hospitals, telephone interviews with physicians working 
at the maternity wards, and pharmacy sales statistics. 
 
Assessment of hospital routines 
A questionnaire was sent to all 52 departments of obstetrics and gynecology in Sweden, 
including questions on starting year, dose, type, route of administration and gestational 
age limits for prophylactic ACS treatment. Telephone interviews with physicians at 
those departments, asking similar questions as in the questionnaires, were also 
performed. Pharmacy sales statistics were thereafter used to confirm or discard the 
information obtained from physicians and questionnaires. Purchased large quantities of 
corticosteroids strengthened information on routine use. Low or no purchased 
quantities confirmed that ACS prophylaxis was not an established intervention.  
 
Pharmacy sales statistics related to number of preterm deliveries 
Information on annual sale volumes of betamethasone and dexamethasone from 1976 
through1997 for each of the 52 departments of obstetrics and gynecology in Sweden 
was abstracted from the Swedish Pharmacy Company. Purchased annual volumes were 
compared with the annual number of preterm deliveries at that specific department. A 
quota was calculated in which the department’s annual corticosteroid volumes were 
divided by their annual number of preterm deliveries.  
 
The recommended prophylactic ACS dose, in case of imminent preterm delivery, is 24 
mg. Therefore the “annual quota cut-point” was set to 20 mg as a limit for routine use. 
Thus, if the calculated quota at a specific department exceeded 20 mg per preterm 
delivery, all infants born at that hospital that year were regarded as exposed. 
 
If the calculated annual quota was less than 10 mg per preterm delivery, all infants born 
at that hospital that year were regarded as unexposed to ACS. If the calculated quota 
was between 10 mg an 20 mg data were regarded as invalid and routine use of ACS 
could not be categorized. Therefore, all children born at that specific department that 
year were excluded from analyses. Further, to reduce the effect that a single delivery 
might have on the calculations, all infants born at hospitals with fewer than 10 preterm 
deliveries per year were excluded. 
 
Validation of exposure algorithm 
To validate our method for estimation of exposure on hospital level, a detailed analysis 
of medical records on a random sample of 120 women was performed in study II. We 
retrieved copies of original medical records, which were thoroughly examined 
regarding information on ACS administration. The exposure estimation at hospital level 
was thereafter compared with the information on ACS as noted in the medical records, 
using medical records as reference method. 
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The quality of exposure classification was evaluated by sensitivity and specificity. 
Sensitivity was the concept used to describe the probability that an individual who was 
actually exposed to ACS, would also be classified as exposed. Specificity was the 
concept used to describe the probability that an individual who was not exposed to 
ACS, would also be classified as unexposed. 
 
Definition of sensitivity and specificity  
 
Sensitivity and specificity displayed by a 2*2 table 
 
Medical record=Reference 
method 
Exposed according to 
exposure algorithm 
Unexposed according to 
exposure algorithm 
Exposed according to 
medical record 
True positive (TP) False negative (FN) 
Unexposed according to 
medical record 
False positive (FP) True negative (TN) 
 
Sensitivity = TP/(TP + FN)  
Specificity = TN/(TN + FP)  
  
  
 
4.3 OUTCOMES IN STUDIES I AND II 
Outcome measures in both studies included Apgar score < 7 at five minutes, RDS, 
BPD, epilepsy and cerebral palsy. In study I, neonatal death was categorized into early 
(0-6 days), late (7-27 days) and post (28-364 days) neonatal death. In study II, neonatal 
death was instead evaluated as stillbirth or overall mortality during the first year of life. 
 
The effect on intraventricular hemorrhage and retinopathy of prematurity was only 
evaluated in study I, whereas effect on childhood diabetes was only evaluated in study 
II. Further, study II evaluated the effect on infant size including birth weight, birth 
length and head circumference in relation to gestational age. Small for gestational age 
(SGA) was defined as a birth weight/ length or head circumference of two standard 
deviations or more below the mean according to sex specific fetal growth curves 
96
.  
 
Information on maternal and infant characteristics and short term outcome such as 
infant size, Apgar score, RDS, intraventricular hemorrhage and retinopathy of 
prematurity were gathered from the Medical Birth Register. Data on long term outcome 
such as epilepsy, cerebral palsy and childhood diabetes were collected from the Patient 
Register. Information on stillbirth and neonatal death were collected from the Cause of 
Death Register.  
 
 
 
   15 
4.4 STUDY POPULATION IN STUDIES III AND IV 
General considerations 
With the overall aim of increasing the knowledge of risk factors for the development of 
BPD, studies III and IV were performed. Study III was explorative and used the cohort 
study design, including all preterm infants born over a 20-year period in Sweden, 
evaluating a broad range of potential risk factors focusing on inflammation. Study IV 
used the case-control study design to address differences in perinatal growth and 
inflammatory risk factors between infants diagnosed with BPD and RDS, respectively. 
Included infants were born extremely and very preterm in an era of modern neonatal 
care. 
 
Study populations  
The cohort in study III was identified through the Swedish Medical Birth Register and 
consisted of all singleton infants, live-born before 37 gestational weeks and surviving 
28 days or beyond during the years 1988 through 2009 in Sweden. In total, 106 339 
infants were included of which 3 388 were born extremely preterm (between 
gestational weeks 22 to 27). 
 
Cases and controls in study IV were identified through the PNQn and included preterm 
infants, live born before 33 completed gestational weeks, during the years 2005 through 
2010 in Sweden. All infants were admitted to a neonatal intensive care unit at birth, and 
survived 28 days or beyond. Cases were infants who were oxygen dependent at 36 
weeks post menstrual age and thereby were considered to have BPD.
49
 Controls were 
infants diagnosed with RDS, but with no oxygen dependence at 36 weeks post 
menstrual age. The controls were matched to cases according to gestational age in 
gestational weeks at birth. To avoid misclassification of cases and inclusion of infants 
with oxygen dependence due to other causes than BPD, all infants born with congenital 
heart and pulmonary malformations were excluded.  
 
4.5 OUTCOME AND RISKFACTORS IN STUDIES III AND IV 
Study III  
Outcome was defined as a diagnosis of BPD during the first year of life, recorded in the 
Patient Register and/or the Cause of Death Register and was assessed by gestational 
age strata for all infants born  preterm (< 37 gestational weeks) and for infants born 
extremely preterm (<28 gestational weeks).  
 
Potential risk factors were categorized into three main areas: maternal chronic 
inflammatory disease, pregnancy related disease and drugs related to treatment of 
inflammation/ infection during pregnancy. 
 
Maternal chronic inflammatory diseases served as indicators for maternal systemic 
inflammation and included Crohn´s disease, ulcerative colitis, psoriatic arthritis, 
rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, systemic 
lupus erythematosus, arthritis associated with Crohn´s disease or ulcerative colitis, 
sarcoidosis, Mb Sjogren, and psoriasis. These diagnoses were searched for in the 
Patient register, starting 10 years prior to delivery. If a maternal diagnosis was 
registered only in connection with outpatient care, 2 outpatient visits were required to 
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qualify as indicator of maternal systemic inflammation. Information on maternal 
asthma, diabetes, endometriosis and psychiatric diseases was also obtained. Maternal 
psychiatric diseases served as a reference marker for increased risk of preterm birth but 
not associated with inflammation. In all analyses, maternal chronic inflammatory 
diseases were analyzed as one entity. 
 
Information on pregnancy related diseases was extracted from the Medical Birth 
Register and included gestational diabetes, preeclampsia related disorders (pregnancy 
induced hypertension, preeclampsia, eclampsia) and chorioamnionitis related disorders 
(amnionitis, chorioamnionitis, prelabor preterm rupture of membranes). Maternal 
genito-urinary infections were categorized into upper urinary tract infections (pyelitis) 
or lower urinary tract infections (cystitis). In all analyses, the preeclampsia related 
disorders were analyzed as one entity and, similarly, all the chorioamnionitis related 
disorders were analyzed as one entity. 
 
Estimation of fetal exposure to drugs related to treatment of inflammation/infection 
during pregnancy was based on prescriptions dispensed to the mothers during 
pregnancy. Anatomical Therapeutic Chemical classification (ATC) codes for 
methotrexate, other disease modifying antirheumatic drugs, TNF-alpha inhibitors, non-
steroid anti-inflammatory drugs, corticosteroids, anti-diabetics and antibiotics were 
searched for in the Prescribed Drug Register. As recording in the Prescribed Drug 
Register started in July 2005, drug exposure was assessed in infants born to mothers 
who had their last menstrual period 90 days after the 1st of July 2005. 
Exposure to methotrexate, other disease modifying antirheumatic drugs and TNF-alpha 
inhibitors were analyzed as one entity, whereas, non-steroid anti-inflammatory drugs, 
corticosteroids and antibiotics were analyzed separately. 
 
Study IV  
Cases with BPD and controls with RDS were compared concerning prenatal exposure 
of factors related to inflammation and growth restriction, risk factors in relation to 
delivery and resuscitation in the delivery room, co-morbidity and postnatal infections, 
ventilation strategies and pharmacological treatments. 
 
As prenatal risk factors related to inflammation or growth restriction, we assessed 
SGA, use of ACS, prelabor preterm rupture of membranes (PPROM), preeclampsia 
related disorders, gestational diabetes, maternal smoking in early pregnancy and season 
of birth as a proxy for exposure to maternal virus infections (winter or summer). 
 
As risk factors in relation to delivery and resuscitation in the delivery room, we 
assessed the effect of mode of delivery (vaginal or cesarean delivery), Apgar score at 5 
minutes, overall resuscitation in the delivery room and interventions as part of 
resuscitation.  
 
As co-morbidity and postnatal infections, we included PDA and related treatment 
(pharmacological or surgical ligation), PPHN, PIE and pneumothorax were included as 
co-morbidity and postnatal infections. The effect of culture positive early and late onset 
infections was also evaluated. Early onset infection was defined as start of symptoms 
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before 72 hours after birth and late onset was start of symptoms 72 hours after birth or 
later.  
 
The association between BPD and ventilation strategies (nasal continuous positive 
airway pressure [nCPAP] and mechanical ventilation) was assessed. The evaluation of 
pharmacological treatments included surfactant, iNO and postnatal steroids.  
 
4.6 STATISTICAL ANALYSES 
In all four studies, the results are presented as odds ratios (OR) and 95% confidence 
intervals (95%CI). In studies I-III, unconditional logistic regression models were used 
to evaluate associations between exposure and outcome. In study IV conditional 
logistic regression was used to evaluate the associations. Logistic regression provides a 
flexible means of analyzing the association between a binary outcome and a number of 
exposure variables.
97
  Conditional logistic regression is a variant of logistic regression 
in which cases are only compared to controls in the same matched set. Additional 
confounders may be included in the model and there is no restriction on the numbers of 
cases and controls in each matched set.
97
 
 
Odds and Odds ratio 
The odds of the event are the ratio of the probability of the event happening divided by 
the probability of the event not happening.  
 
The odds ratio is estimated by: 
 
OR = 
                                
                                      
 
     
     
  
     
     
 
 
d1=diseased in the exposed group d0=diseased in the unexposed group 
h1=healthy in the exposed group h0= healthy in the unexposed group 
 
By the 2*2 table the OR can be expressed as =  
   
   
 
 
Drug/risk factor Cases/diseased Controls/healthy 
Exposed a b 
Unexposed c d 
 
The OR in a cohort study could be interpreted as a Risk Ratio (RR) when the disease is 
rare (prevalence <10%). However, the OR is always further away from 1 than the 
corresponding RR.
97-98
  
 
An OR of 1 indicates no association between the exposure and outcome. A greater 
value than 1 indicates an increased odds of having the disease among exposed subjects. 
A value below 1 indicates decreased odds of having the disease among exposed 
subjects.
97
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Logistic Regression 
Logistic regression allows the analysis of dichotomous or binary outcomes with two 
mutually exclusive levels and the ability to adjust for multiple predictors.
99-100
 Thus, 
logistic regression quantifies the association between a risk factor or treatment and a 
disease, after adjusting for other variables.
99-100
 
 
Logistic regression results are presented by odds ratios because these are the natural 
estimates from the model. The logistic regression model takes the natural logarithm of 
the odds as a regression function of the predictors. With one predictor, X, this takes the 
form ln[odds(Y=1)]=β0+ β1X, where ln stands for the natural logarithm, Y is the 
outcome and Y=1 when the event happens (versus Y=0 when it does not), β0 is the 
intercept term, and β1 represent the regression coefficient, the change in the logarithm 
of the odds of the event with a 1-unit change in the predictor X.
99-100
 
 
Conditional Logistic Regression  
Matching in case-control studies could be done by frequency matching or individual 
matching.
97
 When analyzing individually matched case-control studies we wish to 
control for confounding variables, additional to those matched for in the design. This is 
done by conditional logistic regression, a variant of logistic regressions in which cases 
are only compared to controls in the same matched set. Additional confounders may be 
included in the model and there is no restriction on the numbers of cases and controls in 
each matched set.  
 
Confounders in studies I and II 
In studies I and II, exposure status was estimated at the hospital level. As a true 
confounder should be related to both exposure and outcome, we adjusted for 
confounding factors that could interfere with both hospital of birth and outcome. 
Therefore, year of birth, hospital level and gestational age at birth (study I) and 
pregnancy duration (gestational age) at first hospital admittance by second degree 
polynomial (study II) were identified as potential confounders and adjusted for in the 
statistical analyses.  
 
Confounders in study III 
The following potential confounders were adjusted for: maternal age, birth order, 
hospital level, smoking habits, year of birth and if the mother was born in a Nordic 
country. In addition, we adjusted for birth weight by gestational age (i.e. small for 
gestational age [SGA], large for gestational age [LGA]) when testing the association 
between BPD and preeclampsia related disorders, diabetes mellitus and gestational 
diabetes.  
 
Since logistic regression is based on the assumption that each subject is selected 
independently of the others and observations are not independent in women who 
delivered more than once during the study period, we calculated estimates using 
clustered data in the generalized estimation equation method.  
 
Confounders in study IV 
The following potential confounding factors were adjusted for: maternal age, birth 
order, multiple births and gestational age as additional days in each gestational week.  
   19 
 
In additional stratified analyses, we assessed whether preeclampsia modified the 
association between SGA and BPD, by including both preeclampsia and SGA in the 
model as an interaction term. A p-value below 0.05 was considered statistically 
significant in comparative analyses. 
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5 RESULTS 
 
5.1 STUDIES I AND II 
The cohort in study I consisted of 7 827 infants of which 5 632 were estimated as 
exposed based on the exposure algorithm. The majority of infants were born 
moderately preterm and 17% of the exposed and 15% of the unexposed infants were 
born before 29 weeks of gestation. As this was an observational study, the age 
distribution in the cohort mirrored the actual occurrence in real life with a majority of 
infants being born after 29 weeks of gestation. Less than 5% were born at a primary 
level hospital (local hospital). There were slightly more male than female infants in 
both the exposed (55 %) and the unexposed (56 %) cohort. 
 
The cohort in study II consisted of 11 873 infants, of which 8 620 infants were 
estimated as exposed, based on the exposure algorithm. The majority, 8 323 infants, 
were born at term (gestational week 37 or later) and 3 550 infants were born late 
preterm (gestational weeks 34 to 36).  
 
After adjusting for potential confounders, we found that exposure to ACS before 
gestational week 34 was associated with a reduced risk of RDS in all gestational age 
groups. Of those infants born from gestational week 34 or later, 136 infants were 
diagnosed with RDS and the majority (n=125) was found among those born late 
preterm.  
 
Table 1. Antenatal exposure of corticosteroids before gestational week 34 and the 
risk of respiratory distress syndrome by gestational age at birth (OR=odds ratio, 
CI=confidence interval). 
 
Gestational age at birth (weeks) Adjusted OR Adjusted 95% CI 
<29 0.76 0.56 – 1.02 
<34 0.80 0.70 – 0.92 
≥34 0.50 0.40 – 0.80 
Adjusted for: Level of hospital, birth year, gestational age at birth or pregnancy length by exposure 
 
With the exception of an increased risk of low Apgar score, most pronounced in infants 
born at term, no significant short or long term adverse effects were found. In study II 
the number of BPD events was too few to allow for meaningful analysis. 
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Table 2. Antenatal exposure of corticosteroids before gestational week 34 and the 
risk of Apgar score <7 at 5 minutes by gestational age at birth (OR=odds ratio, 
CI=confidence interval).  
 
Gestational age at birth (weeks) Adjusted OR Adjusted 95% CI 
<34 1.02 0.88 – 1.20 
34-36 1.31 0.83 – 2.07 
≥37 1.60 1.01 – 2.54 
Adjusted for: Level of hospital, birth year, gestational age at birth or pregnancy length by exposure 
 
Among infants born before gestational weeks 34 (study I), male infants exposed to 
ACS had an imprecise risk increase of epilepsy whereas females had a reduced risk 
(OR 1.74, 95% CI: 0.85-3.55 vs. OR 0.50, 95%CI: 0.25-1.03, respectively, p<0.0141). 
Among infants born from gestational weeks 34 or later (study II) there was no 
difference in the risk of epilepsy between male (OR 0.94, 95% CI 0.45 – 1.95) and 
female (OR 0.77, 95% CI 0.29 – 2.05) infants.  
 
5.2 STUDY III 
The study cohort consisted of 106 339 infants. In total, 2 115 infants were diagnosed 
with BPD of whom 1 393 (66%) were born before 28 gestational weeks.  
 
The mothers of infants with BPD were older, had more often a chronic inflammatory 
disease or a pregnancy related disorder and were more often delivered by cesarean 
section. There were more boys than girls in our study cohort and BPD was more 
common among boys.  
 
Preeclampsia related disorders were associated with a 2-fold risk increase of BPD in 
infants born before gestational week 37. In infants born before 28 gestational weeks, a 
30% risk increased was found. The risk estimate was reduced and became imprecise 
when birth weight related to gestational age (SGA) was included in the model (OR 
1.23, 95% CI 0.92 - 2.45). 
 
Table 3. Preeclampsia related disorders (preeclampsia, eclampsia and pregnancy 
induced hypertension) and the risk of bronchopulmonary dysplasia in the infant 
(OR=odds ratio, CI=confidence interval). 
 
Gestational age at birth (weeks) 
Crude 
OR 
Crude 
95%CI 
Adjusted 
OR 
Adjusted 
95%CI 
<28 1.43 1.20 – 1.70  1.33 1.08 – 1.64 
<37 2.05 1.85 – 2.26 2.04 1.83 – 2.29 
Adjusted for: maternal age in 5-year strata, birth order, hospital level, smoking habits, year of birth and mother born in a 
Nordic country.  
 
Chorioamnionitis related disorders and lower urinary tract infections were associated 
with an increased risk of BPD in all infants but not in infants born before gestational 
week 28. No association was seen for upper urinary tract infections. 
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Table 4. Chorioamnionitis related disorders (amnionitis, chorioamnionitis and prelabor preterm rupture of 
membranes) and Lower urinary tract infection and the risk of bronchopulmonary dysplasia in the infant 
(OR=odds ratio, CI=confidence interval). 
 
Gestational age at birth (weeks) 
Crude 
OR 
Crude 
95%CI 
Adjusted 
OR 
Adjusted 
95%CI 
Chorioamnionitis related disorders     
<28 1.00 0.86 – 1.15 0.97 0.81 – 1.15 
<37 1.59 1.44 – 1.74 1.33 1.19 – 1.48 
Lower urinary tract infection     
<28 0.84 0.52 – 1.38 1.03 0.59 – 1.79 
<37 1.71 1.23 – 2.37 1.71 1.19 – 2.45 
Adjusted for: maternal age in 5-year strata, birth order, hospital level, smoking habits, year of birth and mother born in a 
Nordic country.  
 
Maternal diabetes mellitus was associated with a reduced risk of BPD when assessed in 
infants born before gestational week 37, but this association was not significant in 
infants born before gestational week 28. Adjustment for birth weight in relation to 
gestational age (SGA/LGA) did not influence the results. A similar pattern was found 
for gestational diabetes, with reduced risks when analyzed in all infants, but with a non-
significant reduction among extremely preterm infants. In a subgroup analysis, 
including all mothers with available information on insulin treatment and their infants, 
we found associations suggesting reduced risk of BPD in infants of mothers with 
gestational diabetes with insulin as well as without insulin treatment. 
 
Table 5. Diabetes mellitus and gestational diabetes and the risk of bronchopulmonary dysplasia in the 
infant (OR=odds ratio, CI=confidence interval). 
 
Gestational age at birth (weeks) 
Crude 
OR 
Crude 
95%CI 
Adjusted 
OR 
Adjusted 
95%CI 
Diabetes mellitus      
<28 0.64 0.29 – 1.41 0.59 0.24 – 1.41 
<37 0.67 0.46 – 0.99 0.64 0.42 – 0.97 
Gestational diabetes      
<28 0.86 0.37 – 1.97 0.55 0.22 – 1.37 
<37 0.49 0.29 – 0.85 0.36 0.20 – 0.65 
Adjusted for: maternal age in 5-year strata, birth order, hospital level, smoking habits, year of birth and mother born in a 
Nordic country.  
 
Data on maternal drug exposure during pregnancy was available for 28% of infants 
with BPD and for 16% for infants without BPD. Maternal antibiotics were associated 
with a reduced risk of BPD in all infants (OR 0.70, 95% CI 0.52 – 0.96) and in infants 
born extremely preterm (OR 0.52, 95% CI 0.30 – 0.90). No increased risk associated 
with maternal drugs used for chronic inflammatory diseases could be detected. 
 
No increased risk associated with asthma, psychiatric disorders or chronic 
inflammatory diseases were found, but an imprecise risk increase associated with 
endometriosis was seen (OR 2.28, 95% CI 0.96 – 5.42). 
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5.3 STUDY IV 
The study population consisted of 2271 infants, of whom 667 were identified as cases 
with BPD and 1604 as controls with RDS only. Of the BPD cases, 84% had a prior 
diagnosis of RDS. 
 
Prenatal risk factors related to inflammation or growth restriction 
Infants born to women with duration of PPROM more than one week had a more than 
3-fold risk increased of BPD. Twenty-eight percent of the cases and 19% of the 
controls were SGA for birth weight. Factors SGA for length and SGA for birth weight 
were associated with a 50% to 100% increased risk of BPD.  
The majority of mothers of both cases and controls had received prophylactic treatment 
with ACS. For most infants, there was no available information on the exact time point 
of administration. Where information was available, ACS given more than 8 hours 
prior to delivery did not affect the risk of BPD and neither did season of birth, maternal 
smoking in early pregnancy, preeclampsia related disorders or gestational diabetes. In 
the stratified analyses, SGA among infants born to mothers with preeclampsia 
generated a lower adjusted OR of 2.04 (95% CI 1.47-2.83) than SGA without 
preeclampsia (adjusted OR 3.74, 95% CI 2.61-5.35); a statistically significant 
difference (p = 0.008). 
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Table 6. Prenatal risk factors related to inflammation or growth restriction and the risk of bronchopulmonary 
dysplasia in infants born <33 gestational weeks, from 2005 to 2010 in Sweden (OR=odds ratio, 
CI=confidence interval). 
 
Prenatal risk factors 
Crude 
OR 
Crude 
95%CI 
Adjusted 
OR 
Adjusted 
95%CI 
Antenatal corticosteroids     
>8h prior to delivery 1.11 0.79 – 1.57 1.13 0.80 – 1.60 
Given, but time point missing 1.07 0.70 – 1.44 1.10 0.81 – 1.49 
PPROM (time before delivery)     
24h to ≤ 1 week 0.75 0.52 – 1.09 0.76 0.52 – 1.12 
> 1 week 3.18 2.07 – 4.89 3.26 2.11 – 5.02 
Preeclampsia related disorders 1.14 0.89 – 1.48 1.12 0.86 – 1.46 
Gestational diabetes 1.03 0.51 – 2.07 0.97 0.48 – 1.97 
Smoking in early pregnancy 0.77 0.52 – 1.16 0.84 0.55 – 1.27 
Small for gestational age     
Birth weight 2.57 2.00 – 3.35 2.66 2.05 – 3.44 
Length 1.49 1.11 – 1.99 1.49 1.11 – 2.00 
Head circumference 1.06 0.78 – 1.43 1.05 0.78 – 1.42 
Controls with RDS only were matched to cases with BPD according to gestational age by weeks. Conditional logistic 
regression was performed with adjustment for maternal age in 5-year age groups, birth order, multiple births, and 
gestational age by additional days in gestational weeks. ACS=Antenatal Corticosteroids,
 
PPROM=Prelabor Preterm 
Rupture of Membranes, Preeclampsia related disorders=pregnancy induced hypertension, preeclampsia or eclampsia, 
SGA=Small for Gestational Age 
 
Risk factors in relation to delivery and resuscitation in the delivery room 
Low Apgar score was found in 32% of cases and 15% of controls and increased the risk 
of BPD by 35%. Overall resuscitation in the delivery room was required by 91% of 
cases and 77% of the controls. Intubation was required by 56% of the cases and 19% of 
the controls, corresponding to a 53% increased risk of BPD among those requiring 
intubation. Chest compressions were required by 5.0% of cases and 2% of controls, 
corresponding to a 2-fold risk increase of BPD. Cesarean delivery did not affect the risk 
of BPD.  
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Table 7. Risk factors evaluated at delivery and resuscitation in the delivery room, and the risk of 
bronchopulmonary dysplasia in infants born <33 gestational weeks, from 2005 to 2010 in Sweden 
(OR=odds ratio, CI=confidence interval). 
 
Risk factors at delivery and 
resuscitation  
Crude 
OR 
Crude 
95%CI 
Adjusted 
OR 
Adjusted 
95%CI 
Cesarean Section, gestational 
age at birth (weeks) 
    
<27  1.25 0.87 -1.78 1.17 0.80 – 1.73 
≥27  1.41 1.00 – 1.89 1.38 0.97 – 1.95 
Length of resuscitation     
<10 minutes  1.22 0.83 – 1.79 1.17 0.80 – 1.73 
≥10 minutes  1.43 1.01 – 2.02 1.39 0.98 – 1.96 
Supplemental Oxygen  1.01 0.81 – 1.28 1.01 0.80 – 1.27 
Intubation  1.55 1.20 – 2.00 1.53 1.18 – 1.97 
Chest Compressions  1.93 1.09 – 3.41 2.04 1.15 – 3.63 
Apgar <7 at 5 minutes  1.37 1.05 – 1.78 1.35 1.03 – 1.77 
Controls with RDS only were matched to cases with BPD according to gestational age by weeks. Conditional logistic 
regression was performed with adjustment for maternal age in 5-year age groups, birth order, multiple births, and 
gestational age by additional days in gestational weeks. GW=Gestational Week. 
 
Cardiopulmonary co-morbidity and postnatal infections  
PDA was present in 64% of the cases and in 25% of the controls, corresponding to an 
increased risk of BPD by 71%. Pharmacological treatment for PDA was given to 49% 
of cases and 17% of the controls. Surgical ligation was required by 25% of cases and 
3% of controls. Of those surgically treated, 69% had received pharmacological 
treatment prior to surgery. The highest odds ratio related to PDA was seen in infants 
requiring surgical ligation, corresponding to more than 3-fold increased a risk of BPD.  
 
PPHN, PIE and pneumothorax occurred more often among cases than controls and 
were associated with a 2- to 5-fold increased risk of BPD. Mechanical ventilation as 
respiratory support was used in 81% of infants with PIE and in 75% of infants with 
pneumothorax.  
 
Culture positive late onset infections were more frequent among cases than controls. 
One episode of late onset infection increased the risk of BPD by 68% whereas having 2 
or more episodes more than doubled the risk of BPD. The occurrence of a culture 
positive early onset infection was overall similar between cases and controls and did 
not affect the risk of BPD. 
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Table 8. Cardiopulmonary co-morbidity and postnatal infections and the risk of bronchopulmonary 
dysplasia in infants born <33 gestational weeks, from 2005 to 2010 in Sweden (OR=odds ratio, 
CI=confidence interval).  
 
Cardiopulmonary co-morbidity and 
postnatal infections  
Crude 
OR 
Crude 
95%CI 
Adjusted 
OR 
Adjusted 
95%CI 
Patent Ductus Arteriosus     
Overall diagnosis  1.66 1.30 – 2.11 1.71 1.33 – 2.18 
Pharmacological treatment  1.46 1.14 – 1.86 1.48 1.15 – 1.90 
Surgical ligation  3.56 2.41 – 5.26 3.74 2.52 – 5.55 
Persistent Pulmonary 
Hypertension  
5.40 3.02 – 9.65 5.40 3.01 – 9.70 
Pulmonary Interstitially 
Emphysema  
2.51 1.27 – 4.97 2.54 1.28 – 5.07 
Pneumothorax  3.02 1.89 – 4.80 2.99 1.88 – 4.77 
Early infection  1.16 0.62 – 2.19 1.20 0.63 – 2.26 
Late infection     
One episode  1.68 1.29 – 2.18 1.68 1.29 – 2.18 
Two or more episodes  2.53 1.73 – 3.70 2.55 1.74 – 3.74 
Controls with RDS only were matched to cases with BPD according to gestational age by weeks. Conditional logistic 
regression was performed with adjustment for maternal age in 5-year age groups, birth order, multiple births, and 
gestational age by additional days in gestational weeks. Early infection=start  of symptoms less than 72 hours after birth, 
Late infections=start of symptoms 72 hours or more after birth. 
 
Pharmacological treatment and ventilator strategies  
Treatment with surfactant, postnatal steroids and iNO were more common among cases 
than controls. Surfactant treatment corresponded to an increased risk of BPD by 58%. 
Ninety-four percent of those requiring intubation in the delivery room received 
surfactant. Postnatal steroid treatment corresponded to a 10-fold increased risk of BPD. 
Of those treated with postnatal steroids, 80% received mechanical ventilation as 
respiratory support. Treatment with iNO corresponded to almost 7-fold increased risk 
of BPD. PPHN occurred in 60% of the infants receiving iNO. Almost all infants 
received CPAP as respiratory support. More cases than controls required mechanical 
ventilation which yielded a doubled risk of BPD. 
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Table 9. Exposure to pharmacological treatments and ventilation strategies and the risk of 
bronchopulmonary dysplasia in infants born <33 gestational weeks, from 2005 to 2010 in Sweden 
(OR=odds ratio, CI=confidence interval).  
 
Pharmacological treatments 
Crude 
OR 
Crude 
95%CI 
Adjusted 
OR 
Adjusted 
95%CI 
Surfactant  1.60 1.26 – 2.05 1.58 1.24 – 2.02 
Inhaled nitric oxide  6.84 3.24 – 14.41 6.91 3.27 – 14.64 
Postnatal steroids     
Overall   10.01 7.23 – 13.84 10.39 7.48 – 14.45 
Inhalation   11.48 7.65 – 17.22 12.17 8.04 – 18.41 
Injection/per oral 7.82 5.08 – 12.05 7.91 5.12 – 12.22 
Ventilation strategies      
nCPAP 1.26 0.51 – 3.09 1.20 0.49 – 2.94 
Mechanical ventilation  2.11 1.65 – 2.70 2.12 1.65 – 2.71 
Controls with RDS only were matched to cases with BPD according to gestational age by weeks. Conditional logistic 
regression was performed with adjustment for maternal age in 5-year age groups, birth order, multiple births, and 
gestational age by additional days in gestational weeks. nCPAP =Nasal Continuous Positive Airway Pressure. 
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
Study design 
The RCT is the original epidemiologic study design. The RCT could be thought of as 
an epidemiologic experiment in which exposures are assigned by randomization.
98
 The 
randomization process intends to prevent confounding.  
 
The observational cohort design could be described as a natural experiment that 
simulates what would occur in a RCT.
98
 In studies I-III we used the cohort study 
design. A cohort study involves the  measurements of the occurrence of disease within 
cohorts.
98
  A cohort is defined as any designated group of individuals who are followed 
over a period of time. Individuals in the cohort have a common characteristic, such as 
exposure. The cohort study design allows for assessment of  many different disease 
endpoint at the same time.
98
 In studies I-II we investigated one exposure (ACS) and its 
effect of on several disease endpoints. In study III, we explored several prenatal 
exposures and the effect on one outcome: BPD. In study III, exposure data were 
available from the whole population of Swedish preterm infants during a 20 year 
period, allowing us to explore a large number of potential risk factors.  
 
Cohorts could be either closed and opened.
98
 A closed cohort is one with a fixed 
membership and an open cohort can take new members as time passes. Birth cohorts, 
such as in studies I-III,  are always closed cohorts as all individuals enter at the time 
point when they are born, despite the fact that the actual date of study start will differ 
for different individuals.
98
 
 
In study IV, we used the case-control study design which aims at achieving the same 
goals as a cohort study, but more efficiently using sampling.
98
 The starting point in 
case-control studies is the source population, giving rise to the cases. The purpose of 
the control group, which is sampled from the entire source population, is to determine 
the relative size of the exposed and unexposed components of the source population. 
The cardinal requirement of control selection is that the controls are sampled 
independently of exposure status. In study IV, the source population was preterm 
infants, live born before 33 gestational weeks and surviving to 28 days or beyond, from 
year 2005 through 2010 in Sweden. The effect on the outcome, BPD, was investigated 
for a large number of perinatal exposures. 
 
One disadvantage in case-control studies is that sampling from the source population 
could lead to inaccurate measure of the exposure distribution and thereby an incorrect 
risk estimate. Thus, a case-control study may offer less statistical precision in 
estimating the risk ratio than a cohort study of the same population.
98
  To optimize the 
statistical precision in study IV, we included as cases and controls all infants fulfilling 
the eligibility criteria and identified in the PNQn register. Thus, the number of cases 
and control could not be enlarged based on Swedish register data. A way of enlarging 
the source population in future studies would be to identify cases and controls in similar 
registers, for example from all the Nordic health registers, merging data from the 
Nordic population. 
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Matching was used in study IV. The purpose of matching is to improve efficiency. If 
the matching factor is a confounder, the stratified analysis will be more efficient in 
terms of better precision. The cost of matching for a factor is that the effect of that 
factor can no longer be estimated. As gestational age is a strong and well known risk 
factor for BPD, we matched controls to cases in study IV by gestational age in weeks at 
birth. To further increase the precision, gestational age as additional days in each 
gestational week were adjusted for in the statistical analyses. 
 
Logistic Regression and odds ratio in cohort study design 
When comparing an exposed with an unexposed group, the risk ratio (RR) and the odds 
ratio (OR) are both good indicators of the strength of the association between the 
exposure and the disease outcome.
97, 99
 We decided to present our results based on odds 
ratios, even though odds ratios are less easy to interpret than risk ratios (or risk 
differences) 
97
. However, when the outcome is rare (prevalence <10%), the odds ratio is 
a good approximation for the risk ratio.
97-98
 This is because the odds of the occurrence 
of a rare outcome are numerically equivalent to its risk. Therefore, analysis based on 
odds ratio gives the same results as analyses based on risk ratios. Further, for odds 
ratios, the conclusions are identical whether we consider our outcome as the occurrence 
of an event, or the absence of the event. 
 
Logistic regression was used because it allows the analysis of dichotomous or binary 
outcomes with two mutually exclusive levels and provides the ability to adjust for 
multiple predictors.
99-100
 Thus, logistic regression quantifies the association between a 
risk factor or treatment and a disease, after adjusting for other variables. This makes 
logistic regression especially useful for analysis of observational data when adjustment 
is needed to reduce the potential bias resulting from differences in the groups being 
compared.
99-100
 Logistic regression results are typically presented by odds ratios 
because these are the natural estimates from the model and attempts to transform these 
to relative risks can distort the results. 
97, 100
Use of standard linear regression for a two-
level outcome can produce very unsatisfactory results.
97, 100
 Predicted values for some 
covariate values are likely to be either above the level (usually 1) or below the level of 
the outcome (usually 0). In addition, the validity of linear regression depends on the 
variability of the outcome being the same for all values of the predictors. This 
assumption of constant variability does not match the behavior of a 2-level outcome. 
Therefore, linear regression is not adequate for such data.
100
  
 
Errors in epidemiological studies 
Two types of errors afflict epidemiologic studies; random error and systematic error.  
Random errors could be reduced by increasing the study population but this is not the 
case for systematic errors. Another term for systematic error is bias.
98
  Bias could be 
classified into three broad categories; selection bias, information bias, and 
confounding. In all essentials, the same premise for systemic errors applies for both 
cohort and case control studies. 
 
Selection bias occurs when participation in a study is associated with the incidence of 
exposure or outcome studied. In studies I and II, infants born at small hospitals with 
less than 10 preterm deliveries annually and infants born at hospitals with uncertain 
routines for antenatal corticosteroid use were excluded. Further, for inclusion into the 
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cohorts, both studies required that mothers should have been admitted to hospital for 
more than 48 hours to assure a sufficient time period to allow ACS to have been given 
and exhibit full effect. Only singleton infants were included based on the fact that 
multiple birth often is associated with a higher risk of infant morbidity and mortality 
than singleton infants. In studies III and IV, only infants surviving to 28 or beyond 
were included. The reason for the 28 days requirement is that, traditionally, infants are 
diagnosed as having BPD if they have been oxygen dependent for at least 28 days after 
birth.
48
 Further, in study IV, all infants were identified through the PNQn register. 
Reporting to the PNQn register is not compulsory and the coverage was not nationwide 
until 2008. Therefore not all preterm infants born during 2005 through 2010 could be 
identified through the register.  
 
Based on all the reasons for exclusion as outlined above, we may have introduced some 
selection bias in our studies. However, we do not believe that the selection of study 
participants have undermined the study results.   
 
Information bias could occur if information on study subjects is erroneous. If the 
exposure or outcome variable is measured on a categorical scale, erroneous data could 
lead to an individual being placed in an incorrect category and data being misclassified. 
There is a risk of misclassification in our all our studies in which data on exposure 
(studies III-IV) and outcome (studies I-IV) were collected from registers or estimated 
on an algorithm (studies I-II). However, as information in the registers is prospectively 
collected by the treating physician at the time of hospitalization, it is unlikely that data 
suffer from patient non-response bias or recall bias. 
 
In study II, a validation of the exposure algorithm was performed, using medical 
records. A higher number of individuals were considered exposed based on our 
predefined method as compared to what was identified in the medical records, which 
yielded low specificity. When reviewing the medical records we found that information 
concerning decisions whether to treat or not with ACS was often completely lacking. In 
addition, written notes of actual ACS administration were surprisingly poor and 
inconsistently given in different parts of the records. Considering this, one possible 
explanation for the low specificity is poor documentation i.e. that ACS sometimes was 
administered without notification in the medical records. Another possibility is that our 
predefined method actually overestimated exposure status. Nevertheless, if 
misclassification occurred, we believe that it would be non-differential, i.e. not 
dependent on the person’s disease or exposure status and, if anything, it would produce 
estimates that are diluted. 
  
Confounding is a systematic error and could be thought of as a mixing of effects.
98
 For 
confounding to occur, confounding the factor must be imbalanced between the 
compared groups. A confounding factor must be associated with the disease, either as a 
cause or as a proxy for a cause, but not as an effect of the disease. Further, a confounder 
must be associated with the exposure, but must not be an effect of the exposure. It 
should be noticed, that a factor which is an effect of the exposure and an intermediate 
step in the causal pathway from exposure to disease is not confounder.  A causal 
intermediate is part of the effect that one wishes to study.  
 
   31 
Confounding could be handled in the data analysis by stratification and regression 
models. In all our studies, potential confounding factors were identified before study 
start and adjusted for in the logistic regression analyses. Stratification is basically cross-
tabulation of data on exposure and disease by categories of one or more variables that 
are potentially confounding variables. Stratified analyses were performed in study II 
and outcomes were evaluated for infants born late preterm and infants born at term. 
Other common ways of controlling for confounding in epidemiological studies are 
restriction and matching.  
 
Potential confounders in studies I and II 
In studies I and II, exposure status was estimated at the hospital level. As a true 
confounder should be related to both exposure and outcome, we adjusted for 
confounding factors that could interfere with both hospital of birth and outcome. 
Therefore, year of birth, hospital level and gestational age at birth (study I) and 
pregnancy duration (gestational age) at first hospital admittance by second degree 
polynomial (study II) were identified as potential confounders and adjusted for in the 
statistical analyses. Year of birth adjusted for differences in neonatal care during 
different years. Hospital level was included as there is evidence that the risk of neonatal 
mortality and morbidity is higher in preterm infants born at hospitals providing basic 
care as compared to infants born at hospitals with specialized neonatal care.
2, 101
 As 
exposure was estimated on hospital level, we did not adjust for individual factors, such 
as gestational diabetes or maternal infections during pregnancy, which could influence 
whether a specific individual was given ACS or not. 
 
Potential confounders in studies III and IV 
Maternal age and birth order were adjusted for in both studies III and IV. Maternal age 
was included as confounder since increasing maternal age is associated with an 
increased risk of adverse pregnancy outcome in general. In addition, birth order is 
correlated to the age of the mother, as women giving birth to their second or third child, 
are generally older than mothers giving birth to their first child.  
 
In study III, we further adjusted for hospital level, smoking habits, year of birth and if 
the mother was born in a Nordic country. Year of birth adjusted for differences in 
neonatal care during different years. Whether the mother was born in a Nordic country 
or not adjusted for increased risk of adverse pregnancy outcome related to ethnic 
background. In addition, we adjusted for birth weight by gestational age (i.e. small for 
gestational age [SGA], large for gestational age [LGA]) when testing the association 
between BPD and preeclampsia related disorders, diabetes mellitus and gestational 
diabetes. The rationale for this is that preeclampsia is associated with decreased fetal 
growth whereas diabetes mellitus/gestational diabetes is associated with increased fetal 
growth. 
 
In study IV, we also adjusted for multiple births and gestational age as additional days 
in each gestational week. Multiple births were adjusted for because it is often 
associated with a higher risk of infant morbidity and mortality. Gestational age was 
adjusted for as controls were matched to cases according to gestational age at birth and 
there is a risk of introducing bias if adjustment for the matching factor is not done in the 
logistic regression analysis. 
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Internal and external validity and precision 
Internal validity is related to the accuracy of the study results. If the study result is 
trustworthy and close to the true value in the studied population, the internal validity is 
high. Bias and confounding have negative effects on internal validity. In all studies, 
effort were made to identifying potential confounders which to be adjusted for in the 
statistical analysis. Further, by using prospectively collected register data, recall bias 
and patient non-response bias are minimized, which increases the internal validity of 
the study results. 
 
External validity is related to the generalizability of the study results. If the study result 
could be extrapolated to the results of a larger population, the external validity is high. 
External validity is sensitive to selection bias. In our studies we included the whole 
Swedish population of infants that fulfilled the study criteria, during the actual study 
period and the study results could be generalized to populations of preterm infant born 
in an era of modern neonatal care.  
 
Precision is related to random errors and could be reduced by increasing the number of 
subject in study population. 
  
Effect modification 
Interaction can be statistical or biologic, causal (synergism, antagonism). There is 
substantial confusion surrounding the evaluation of interaction, much of which stems 
from the fact that the term is used differently in statistics and epidemiology.
98
 In 
statistics, the term interaction is used to refer to departure from the underlying form of a 
statistical model. Biologic interaction between two potential causes occurs whenever 
the effect of one is dependent on the presence of the other. When interaction is present, 
the association between the risk factor and outcome variable is not constant over 
different levels of the interacting covariate. That is, the interacting covariate modifies 
the effect of the risk factor. Therefore, any statement about the risk factor or exposure 
effect will have to specify the covariate level. 
 
Summary 
Assessing the effects of exposure (drug treatment or diseases) in a clinical setting is 
more complex than in the context of a RCT. Our design (observational cohort studies 
and case-control study) does not allow us to firmly conclude that it is exclusively the 
exposure in itself that caused the association with the outcomes. We tried, however, to 
compensate for all potential shortcomings by ascertaining both exposure and outcome 
and adjusting for identified potential confounders. Nevertheless, the risk of 
misclassification of exposure or outcome could not be disregarded. However, if 
misclassification is present it is more likely to be non-differential, which would dilute 
the association between exposure and outcome. In addition, the result was in line with 
the result from previous RCTs.
7, 32
 As all these studies emerge from a large nationwide 
population, the results could be generalized to infants born in industrial countries in an 
era of modern neonatal care. 
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6.2 DISCUSSION OF THE RESULTS 
The overall aim of this thesis was to evaluate the comprehensive health consequences 
of the widespread routine treatment with ACS to women with imminent preterm 
delivery and to increase the knowledge of risk factors implicated in the development of 
BPD. 
 
The results from studies I and II confirm that treatment with ACS reduces the 
occurrence of RDS in the population of infants that actually receive the treatment in 
real life, with no apparent increased risk for long-term adverse effect. Not only infants 
born before gestational week 34 will benefit from the treatment, also exposed infants 
born at a later gestational age had a reduced risk of RDS. This indicates a prolonged 
beneficial effect of previous ACS treatment. Study III found that preeclampsia was a 
strong risk factor for BPD and that gestational diabetes and diabetes mellitus decreased 
the risk. The overall conclusion from study IV is that infants who later on develop BPD 
are more severely ill already at birth. Infants who developed BPD had more often been 
exposed to long duration of PPROM, they were more often SGA and had lower Apgar 
scores and required resuscitation interventions in the delivery room at a higher rate as 
compared to infants with RDS but not developing BPD. These findings indicate that 
infants subsequently developing BPD had been exposed to factors causing lung injury 
and triggering inflammation already during fetal life. 
 
6.2.1 Studies I and II 
The magnitude of effect on RDS in our observational study was not as large as reported 
from reviews of RCT.
7, 32
 However, assessing the effect of a single procedure in a full 
clinical setting is more complex than using the experimental design of an RCT. Other 
postnatal treatments that could not be controlled for in the study could have 
compensated for lack of prenatal treatment.  
 
Studies I and II contribute to the knowledge of long-term effects of ACS, data which 
could not have been sufficiently achieved from RCTs. None of our studies could detect 
any apparent adverse long-term neurological effect and no increased risk of neonatal 
death was seen. The only significant adverse finding was an increased risk of low 
Apgar score in exposed infants born term. Low Apgar score could be related to long-
term neurological effects such as epilepsy or cerebral palsy or impact on more subtle 
neurosensory outcomes, such as school performance and intellectual capacity. We 
included nearly 12 000 infants in study II and found no increased risk of epilepsy or 
cerebral palsy. Whether the finding of low Apgar score had any clinical significance on 
school performance cannot be concluded as no such endpoints were possible to 
evaluate.   
 
To assess rare outcomes, large populations are needed to be followed for a long period 
of time. Major limitations of previous observational studies have been the small 
number of included infants.
7, 102
  By using the observational cohort design and 
extracting data from national registers we managed to include the majority of Swedish 
preterm newborns during a 20 year period and follow the children during their first 
decade in life. The lack of significant long-term adverse effects adds valuable 
information to the knowledge of the total health consequences of ACS treatment. 
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When comparing the numbers of infants identified as preterm, late preterm and term in 
both studies, the proportion of false imminent preterm deliveries and the number of 
women in whom pregnancy continued to term was surprising as it was larger than the 
proportion of preterm births. A previous publication reported that approximately 25% 
of women presenting with imminent preterm delivery will not deliver until after one 
week or more.
103
 However, our data indicate that the proportion of false imminent 
delivery might be even larger. As both studies were observational studies, the 
gestational age distribution in the study cohorts mirrored the actual age distributions in 
real life. In study I, 7 827 infants were born preterm which should be compared with 
the 11 873 infants identified in study II who were born to women admitted to hospital 
for imminent preterm delivery but who gave birth late preterm or term. This illustrates 
that for every suspected preterm delivery, giving rise to an infant born before 
gestational week 34, there will be another one or two infants born at a later gestational 
age.  
 
The clinical judgment whether preterm delivery is inevitable or not is difficult and 
impacts on the decision whether to give ACS or not.  In this aspect, our studies cannot 
contribute to any new knowledge facilitating the decision on which women should 
receive treatment with ACS or not. Future studies should focus on identifying those 
women who actually will proceed into preterm delivery among all women presenting 
with perceived preterm labor. As a large number of these women will not give birth 
within a short period of time, the question of repeated ACS treatment will arise. As 
there is uncertainty over the benefits and long term adverse effects of repeated courses 
of ACS given 7 days after the previous course, future research should focus on 
evaluating repeated course of ACS.  
 
6.2.2 Study III 
In line with other publications, the results in study III show that preeclampsia was a 
strong prenatal risk factor for BPD development.
104
 The effect was apparent in all 
infants born preterm and in extremely preterm infants. The pathophysiology of 
preeclampsia is not completely understood but it is primarily a vascular disease, 
induced by an imbalance in angiogenetic factors.
105-108
 The increased risk for BPD 
could be related to inflammatory mechanism but an impaired angiogenesis may also 
play a significant role.
23, 109
 Although not statistically significant, we found a doubled 
risk of BPD in extremely preterm infants, born to women with endometriosis. This 
finding could also be associated with an impaired angiogenesis. Therefore, further 
studies investigating associations between BPD and diseases in which angiogenetic 
factors may play a role are warranted. 
 
In contrast to the increased risk of BPD associated with preeclampsia, a reduced risk 
associated with maternal diabetes mellitus and gestational diabetes was found. The 
mechanism behind such a protective effect is unclear and we tried to explore whether 
the effect was related to the disorder itself, its treatment or other factors related to the 
disorder. Maternal diabetes is commonly associated with an increased risk of 
accelerated intrauterine growth and large for gestational age infants, whereas 
preeclampsia is associated with an increased risk of growth restriction.
110-111
 To explore 
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the impact of birth weight, we performed additional analyses adjusting for birth weight 
by gestational age (SGA/LGA), but found only minor effects on the risk estimates. To 
further adhere to the assumption of an impaired angiogenesis as part of the causal 
pathway of BPD, one could hypothesize how insulin treatment during pregnancy may 
act as a protective factor. Insulin, being a growth hormone, may promote angiogenesis 
and facilitate vascular pulmonary development. To investigate the role of insulin 
treatment during pregnancy, we performed additional analyses, separately assessing 
infants born to gestational diabetic mothers with and without insulin, but found no 
protective effect of insulin treatment on the risk of BPD. Considering the diabetic 
disorder itself, one could speculate that a poor metabolic control during pregnancy 
causing infant hypoglycaemia in the postnatal period might initiate infant stress 
reactions and increase endogenous corticosteroid levels, thus, promoting lung 
maturation in the newborn infant. However, we did not succeed in clarifying the 
mechanism and the protective effect of diabetes remains puzzling. To our knowledge, 
no published study has specifically investigated this association but the result is in line 
with the higher rates of BPD in non-diabetic mothers previously reported by Bental et 
al.
112
 Additional studies are needed to further investigate the association.  
 
The role of chorioamnionitis in BPD development is unclear and the results from 
previous studies are ambiguous. Our findings of an increased risk in all infants born 
before gestational week 37, but not in infants born extremely preterm, do not clarify 
whether chorioamnionitis is a true risk factor or not. 
  
We also found an association between lower urinary tract infections and risk of BPD in 
infants born before 37 gestational weeks in general, but not specifically in infants born 
extremely preterm. According to published literature, lower urinary tract infection does 
not seem to be related to adverse pregnancy outcome.
113
 Additional studies are needed 
to confirm or reject our finding of an increased risk of BPD associated with lower 
urinary tract infections.  
 
Antibiotics were associated with a decreased risk of BPD and it appears that maternal 
antibiotic treatment might have beneficial effect on BPD. One possible explanation is 
that drug treatment during pregnancy could be a proxy for closer pregnancy follow-up, 
which could influence the outcome of pregnancy. 
 
One of the main objectives of this thesis was to investigate whether maternal 
inflammatory diseases affected the risk of BPD development. No apparent association 
was found between BPD and maternal chronic inflammatory diseases or use of anti-
inflammatory drugs. Thus, maternal inflammatory diseases in general do not seem to 
increase the risk for BPD. However, a weakness in our study was that we did not have 
access to information on maternal disease flare or remission. We could therefore not 
estimate the magnitude of maternal systemic inflammation on exposed infants. As 
development of BPD is multi-factorial including several causal factors for which 
duration and magnitude of exposure may play significant roles, our results do not allow 
conclusions regarding risks in infants exposed to high level of maternal systemic 
inflammation, such as that occurring in relation to a flare.  
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6.2.3 Study IV 
A relevant clinical question is how to identify those infants at higher risk of BPD, 
among those preterm infants presenting with respiratory problems. An early 
identification of infants at risk, requiring more support and intensive treatment, is likely 
to be beneficial for the infants and an advantage for planning strategies at neonatal 
intensive care units.
114
  
 
Study IV compared infants with BPD with infants with RDS only, as we found such 
comparison of more relevance for the clinical situation than comparison with an 
unselected group of infants as done in most previous studies.
61, 63, 115
  Study III also 
investigated risk factors for BPD development but a major difference between these 
two studies is the comparison group, which in study III was an unselected group of 
preterm infants. The importance of a specific risk factor could differ in these 
populations. To our knowledge no previous published study has focused on the specific 
comparison between infants with BPD and infants with RDS only. 
 
Growth related risk factors 
SGA doubled the risk of BPD. An SGA neonate may be constitutionally small but 
more often SGA is the consequence of utero-placental insufficiency.
116
  Utero-placental 
insufficiency is associated with inflammatory or vascular disorders, for example 
preeclampsia.
117
 In study IV, we tested whether preeclampsia was the underlying cause 
behind the association between SGA and BPD and found an interaction. Somewhat 
surprising, the effect of SGA on BPD development was higher among growth restricted 
infants due to other causes than preeclampsia as compared to the effect of SGA related 
to preeclampsia. Preeclampsia is a temporary disease, usually starting late in gestation. 
Both mother and infant will usually recover from symptoms shortly after delivery.
118
 
The finding that other factors than preeclampsia had a greater impact on BPD in 
relation to SGA, may suggest that other unknown factors causing irreversible growth 
restriction of the lungs may play a role in the development of BPD. Further, no 
association with BPD was found with other growth related factors, such as gestational 
diabetes and maternal smoking. In study III, we also investigated the effect of 
preeclampsia on BPD and found that preeclampsia was a strong prenatal risk factor in 
all preterm infants and infants born extremely preterm.  One reason for diversity in 
result is the difference in comparison group. The importance of preeclampsia as a risk 
factor could differ in these populations. 
 
Inflammatory risk factors 
Duration of PPROM exceeding one week tripled the risk of BPD. PPROM could be 
seen as a proxy for chorioamnionitis as bacterial infection is the main cause for 
membrane rupture. Moreover, PROM has been shown to correlate to clinical and 
histological chorioamnionitis.
119-120
  Whether chorioamnionitis is a risk factor for BPD 
has not been established but in preterm infants exposure to inflammation related to 
chorioamnionitis has been proposed as a risk factor since intra-amniotic endotoxin 
exposure can disrupt alveolar development.
121
  The effect of chorioamnionitis was also 
investigated in study III with a somewhat indistinct result, showing an increased risk in 
infants born before gestational week 37 in general, but not specifically in extremely 
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preterm infants.  The finding in study IV supports the association between 
chorioamnionitis and BPD.  
 
Severe postnatal infections have been shown to increase the risk of BPD, which is 
supported by our finding of higher risk of BPD with more episodes of infection.
122
 
However, there is a complex interplay between several of the investigated risk factors. 
The risk of severe infection increases with longer duration of ventilator support and 
infants with severe infections have an increased risk of a reopening of PDA and PDA 
increases the risk of BPD.
122
 Nevertheless, our finding underscores the importance of 
strategies to reduce infections in preterm infants. 
  
Interventions in relation to delivery 
Infants who subsequently develop BPD had lower Apgar score and higher needs of 
resuscitation in the delivery room as compared to infants with RDS. This strengthens 
the assumption of prenatal factors causing lung injury as part in the causal pathway of 
BPD development. However, resuscitation interventions per se may also cause lung 
injury and it is difficult to establish whether these interventions were required because 
of the lung injury or actually caused it.
123-124
  
 
Associated co-morbidities 
A substantial difference in the occurrence of co-morbidity was noticed as infants with 
BPD more often suffered from other conditions. Presumably, several of the assessed 
co-morbidities are not risk factors per se, but rather co-factors and it has not been 
possible to separate true risk factors from factors that might co-exist with BPD. 
 
We found a strong association between PDA and BPD with the highest risk in infants 
requiring surgical ligation. Fluid overloads and surgical ligation of PDA have been 
suggested as causal factors of BPD.
45-46, 50
 Although it is difficult to determine if the 
increased risk is due to the ligation itself, we propose that the association is related to 
other factors such as prolonged exposure to PDA which might coexist in infants who 
require ligation. In infants with PPHN, we found a 5-fold increased risk of BPD and 
both PIE and pneumothorax more than doubled the risk of BPD. However, the majority 
of infants with PIE and pneumothorax received mechanical ventilation and the 
observed association with PIE and pneumothorax might be a consequence of the 
respiratory support. 
 
Pharmacological treatment  
ACS is a clinically relevant modulator of lung maturation which reduces the incidence 
of neonatal death and RDS in preterm birth. It has been suggested that ACS may 
increase the risk of BPD, but our results do not support such an association. The 
increased risk associated with postnatal steroid treatment probably mirrors the more 
severe respiratory morbidity seen in infants with BPD.  
 
In summary, the results from study IV show that both pre- and postnatal factors related 
to growth restriction and inflammation were associated with an increased risk of BPD. 
Presumably, several of the assessed postnatal factors are not risk factors per se, but 
rather co-factors. An infant presenting with respiratory problems and born after 
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PPROM or as SGA with low Apgar score, and who requires resuscitation in the 
delivery room should alert the suspicion of subsequent development of BPD. 
 
6.2.4 Mode of delivery in studies I-IV 
Cesarean section increases the risk for postnatal respiratory morbidity in general and 
has been shown to be a risk factor for RDS.
25-26, 125
  
 
Studies I-II evaluated the effect of ACS exposure on both short and long term 
outcomes. Information on mode of delivery (vaginal or cesarean section) was not 
available in these studies. Further, we did not consider mode of delivery as related to 
whether an infant was classified as exposed to ACS or not at hospital level. Therefore 
mode of delivery was not included as a potential confounder in studies I and II. 
 
In study III data on mode of delivery was available and presented as maternal and 
infant characteristics in Table 1. Cesarean section was far more common in infants with 
BPD. The primary objective of study III was to evaluate prenatal inflammatory risk 
factors and cesarean section did not qualify for that criteria. Therefore, cesarean section 
was not evaluated as a risk factor. To test whether mode of delivery modified the effect 
of a risk factor we carried out additional analyses including cesarean delivery as effect 
modifier. Only minor changes on the risk estimates were seen.  
 
Table 10. Exposure to cesarean section and the occurrence of bronchopulmonary dysplasia (BPD) in 
infants born before 37 gestational weeks included in study III presented in a 2*2 table. 
 
Cesarean section BPD Yes BPD No 
Yes 64.1% 34.6% 
No 35.9% 65.4% 
 
In study IV, the effect of mode of delivery was evaluated in infants born before 27 
gestational weeks and in infants born from gestational week 27 to gestational week 32. 
In both age groups an increased risk estimate was found among those delivered by 
cesarean section but none of the risk estimates was statistically significant. 
 
Table 11. Cesarean section and  the risk of bronchopulmonary dysplasia by gestational 
age in infants included in study IV (OR=odds ratio, CI=confidence interval). 
 
Gestational age at birth (weeks) Adjusted OR Adjusted 95%CI 
< 27 1.27 0.89 – 1.82 
≥ 27 1.38 0.97 – 1.95 
 
6.2.5 Gender distribution in studies I-IV 
There were more male than female infants in the study population of all our studies. 
Boys have higher perinatal mortality and morbidity in general and higher risk of 
preterm birth. Both RDS and BPD and other respiratory diseases are more common in 
boys than in girls.
126-127
  
 
The understanding of whether sex impacts on the risk of BPD development may add 
valuable information of which infant that is at risk and will require more intensive care 
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interventions. However, sex of the infant is not a variable that could be prevented in 
order to reduce the risk of BPD.  
  
Table 12. Distribution of infant gender among infants exposed or unexposed to antenatal corticosteroids 
(ACS) in study I and II. 
 
Sex Exposed to ACS Unexposed to ACS 
Study I   
Female 45.2% 43.8% 
Male 54.8% 56.2% 
Study II   
Female 45.9% 44.6% 
Male 54.1% 55.4% 
  
In study I, we performed analyses stratified according to gender. With the exception of 
epilepsy, there was no difference in the short and long term risk between male and 
female infants. Both male and female infants had a reduced risk of RDS after ACS 
exposure and no association with BPD was seen.  In study II, the BPD events were too 
few for meaningful analysis. 
 
Table 13. Exposure to antenatal corticosteroids and the risk of respiratory distress syndrome (RDS) and 
bronchopulmonary dysplasia (BPD) by gender in study I (OR=odds ratio, CI=confidence interval).  
 
 Male Female 
 Adjusted 
OR 
Adjusted 
95%CI 
Adjusted 
OR 
Adjusted 
95%CI 
RDS 0.76 0.64 – 0.90 0.88 0.72 – 1.08 
BPD 0.78 0.52 – 1.17 1.04 0.61 – 1.78 
 
The population in studies III and IV also consisted of more boys than girls and BPD 
was more common among boys. A reason for the higher number of boys in these 
studies is that preterm birth and neonatal morbidity is more common in boys than girls. 
 
Table 14. Distribution of infant genders among infants with and without bronchopulmonary dysplasia 
(BPD) in study III and IV. 
 
Sex BPD Yes BPD No 
Study III  * 
Female 37.0% 45.9% 
Male 63.0% 54.1% 
Study IV  ** 
Female 38.1% 44.3% 
Male 61.9% 55.7% 
* All infants born before 37 gestational weeks 
** Infants diagnosed with RDS and born before 33 gestational weeks.  
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7 CONCLUSIONS 
 The prophylactic use of ACS in the clinical setting in modern neonatal care has 
a similar beneficial magnitude on RDS as previously shown in RCTs and 
treatment is not afflicted with any apparent increased risk of negative long-term 
neurosensory outcomes such as epilepsy or CP. 
 
 Infants born late preterm have prolonged beneficial effect of earlier 
corticosteroid exposure with reduced risk of RDS. For infants born at term, the 
total treatment effect was less beneficial as they had increased risk of low 
Apgar score. 
 
 Preeclampsia is a strong risk factor for development of BPD in preterm infants. 
Maternal diabetes mellitus and gestational diabetes reduced the risk of BPD, 
implying that an impaired angiogenesis could be added to the possible 
etiological factors that contribute to BPD development. 
 
 Both pre- and postnatal factors related to growth restriction and inflammation 
are associated with an increased risk of BPD. An infant presenting with 
respiratory problems and born after PPROM or as SGA with low Apgar score 
and resuscitated in the delivery room should alert the suspicion of subsequent 
development of BPD. 
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8 FUTURE PERSPECTIVE 
There is an uncertainty over the benefits and long term adverse effects of repeated 
courses of ACS given 7 days after the previous course. Future research should focus on 
evaluating repeated course of ACS before this could be routinely recommended. 
 
Future studies should focus on identifying those factors responsible for intrauterine 
growth restriction and associated with development of BPD. 
 
Further investigations concerning associations between diseases in which angiogenic 
factors play a role and BPD are warranted. 
 
The susceptibility of some infants for BPD development may not be only 
environmental, but also genetic. Studies on genetic association may add further 
knowledge to the etiology of BPD development.  
 
Major questions remain concerning growth of the lungs through childhood and adult 
age in those diagnosed with BPD. Research should focus on long term follow-up of 
infants with BPD.  
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